Industry Focus
Healthcare: Were These The 3 Most Promising Biotech Stocks To Buy After ASCO?
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:24:27
- Mas informaciones
Informações:
Sinopsis
Bluebird bio, TG Therapeutics, and Loxo Oncology investors are smiling following bullish presentations for their respective cancer drugs at the annual American Society of Clinical Oncology conference this week. Sponsored link: http://www.casper.com/fool code fool.
